Analysts project four medications will achieve blockbuster status of $1 billion or more in annual sales: Xtandi from Medivation and Astellas Pharma for prostate cancer; the blood thinner Eliquis from Bristol-Myers Squibb and Pfizer; Revlimid from Celgene for multiple myeloma; and the next-generation type 2 diabetes drug Invokana from Johnson & Johnson. The Motley Fool (10/26)